The Polish star’s 30-day suspension and the discourse around it underscore tennis’s mounting credibility issue.

Swiatek said she couldn't play over the fall owing to 'personal matters'. That didn't really explain what was going on

The results for unspecified substances resulted in a mandatory provisional suspension, imposed on September 12th. This resulted in the Pole having to miss the WTA 500 in Korea (September 16-22), the WTA 1000 in Beijing (September 25-October 6) and the WTA 1000 in Wuhan (October 7-13).

Swiatek said a batch of melatonin she used was contaminated with a banned substance, an explanation anti-doping authorities said they accepted after a probe.

The five-time Grand Slam champion has served 22 days of a one-month ban from tennis. Here's what you need to know

Iga Swiatek received a one-month ban after positive drug test and will be eligible to play in the Australian Open.

World number two Iga Swiatek has accepted a one-month suspension after testing positive for the prohibited substance trimetazidine (TMZ).

Meanwhile, Swiatek was found to have been “at the lowest end of the range for no significant fault or negligence” after the 23-year-old Polish player explained that her doping violation was caused by a contaminated supply of the non-prescription medication melatonin, which she uses to help with jet lag and sleep issues.

Iga Swiatek hopes to put the one-month doping ban behind her as quickly as possible, as she aims to get back on track in 2025.

WTA World No. 2 Iga Swiatek continues to make changes to her team in the last few months of 2024. After almost four years, Swiatek has parted ways with her Public Relations Manager, Paula Wolecka. According to a statement from the Polish public relations agency PRoto,

Iga Swiatek's doping controversy refuses to die down. The post Tennis Controversy: Iga Swiatek’s Doping Drama Highlights Double Standards as Frustrated Insider Minces No Words appeared first on EssentiallySports.